Radioiodine treatment of well-differentiated thyroid cancer

Endocrine

Volumn 42, Issue 3, 2012, Pages 506-513

  Wartofsky, Leonard ^a   Van Nostrand, Douglas ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RECOMBINANT PROTEIN; THYROTROPIN;

CANCER STAGING; DIFFERENTIATED THYROID CANCER; DOSIMETRY; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; THYROIDECTOMY; TREATMENT INDICATION; TUMOR ABLATION; WHOLE BODY SCINTISCANNING; NOMENCLATURE; PATHOLOGY; RADIATION RESPONSE; THYROID TUMOR;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; RECOMBINANT PROTEINS; TERMINOLOGY AS TOPIC; THYROID NEOPLASMS; THYROTROPIN;

EID: 84878240228     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9729-5     Document Type: Review

References (47)

1. S.M. Seidin, L.D. Marinelli, E. Oshry, Radioactive iodine therapy effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132, 838-847 (1946)
2. W.H. Beierwaltes, R. Rabbani, C. Dmuchowski et al., An analysis of ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J. Nucl. Med. 25, 1287-1293 (1984)
3. M. Schlumberger, C. Challeton, F. De Vathaire et al., Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37, 598-605 (1996)
4. T. Petrich, A. Widjaja, T.J. Musholt et al., Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side effects and influence of age. Eur. J. Nucl. Med. 28, 203-208 (2001)
5. A.P. Brown, W.P. Greening, V.R. McCready, H.J. Shaw, C.L. Harmer, Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden hospital experience. Br. J. Radiol. 57, 323-327 (1984)
6. C. Menzel, F. Grunwald, A. Schomburg et al., "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J. Nucl. Med. 37, 1496-1503 (1996)
7. E. Hindié, D. Melliere, F. Lange et al., Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur. J. Nucl. Med. 30, 974-981 (2003)
8. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009)
9. F. Pacini, M. Schlumberger, H. Drale et al., European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787-803 (2006)
10. F. Atkins, D. Van Nostrand, Radioiodine Whole Body Imaging, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, ed. by L. Wartofsky, Van Nostrand (Humana Press, Totowa, 2006), pp. 133-150
11. R. McDougal, in Differentiated Thyroid Cancer, ed. by R. McDougal. Management of Thyroid Cancer and Related Nodular Disease (Springer, New York, 2006), p. 173
12. D. Van Nostrand, M. Aiken, F. Atkins, S. Moreau, C. Garcia, E. Acio, K. Burman, L. Wartofsky, The utility of radioiodine scans prior to iodine-131 ablation in patients with well differentiated thyroid cancer. Thyroid 19, 849-855 (2009)
13. M.-K. Chen, M. Yasrebi, J. Samii, L.H. Staib, I. Doddamane, D.W. Cheng, The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid 22, 304-308 (2012)
14. M.J. Schlumberger, F. Pacini, The low utility of pre-therapy scans in thyroid cancer patients. Thyroid 19, 815-816 (2009)
15. D. Van Nostrand, F. Atkins, F. Yeganeh et al., Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12, 121-134 (2002)
16. H.R. Maxon, S.R. Thomas, V.S. Hertzbert, J.G. Kereiakes, I.W. Chen, M.I. Sperling, E.L. Saenger, Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med. 309, 937-941 (1983)
17. S.R. Thomas, H.R. Maxon, J.G. Kereiakes, In vivo quantitation of lesion radioactivity using external counting methods. Med. Phys. 3, 253-255 (1976)
18. R.S. Benua, N.R. Cicale, M. Sonenberg, R.W. Rawson, The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87, 171-182 (1962)
19. G. Sgouros, Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med. 34, 689-694 (1993)
20. R. Dorn, J. Kopp, H. Vogt et al., Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-based approach. J. Nucl. Med. 44, 451-456 (2003)
21. R. Leeper, Controversies in the treatment of thyroid cancer: the New York Memorial Hospital approach. Thyroid Today 5, 1-4 (1982)
22. K. Kulkarni, D. Van Nostrand, F.B. Atkins, M.J. Aiken, K. Burman, L. Wartofsky, The frequency with which empiric amounts of radioiodine "over-" or "under-" treat patients with metastatic well-differentiated thyroid cancer. Thyroid 16, 1019-1023 (2006)
23. R.M. Tuttle, R. Leboeuf, R.J. Robbins et al., Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J. Nucl. Med. 47, 1587-1591 (2006)
24. J. Klubo-Gwiezdzinska, D. Van Nostrand, F. Atkins, K. Burman, J. Jonklaas, M. Mete, L. Wartofsky, Efficacy of dosimetric versus empiric prescribed activity of 131-I for therapy of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 3217-3225 (2011)
25. D. Van Nostrand, Radioiodine Ablation, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd edn., ed. by L. Wartofsky, D. Van Nostrand (Humana Press, Totowa, 2011), pp. 611-612
26. D. Van Nostrand, Radioiodine Treatment for Distant Metastases, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd edn., ed. by L. Wartofsky, D. Van Nostrand (Humana Press, Totowa, 2006), pp. 611-612
27. M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet et al., Strategies of radioiodine ablation in patients with low risk thyroid cancer. N. Engl. J. Med. 366, 1663-1673 (2012)
28. U. Mallick, C. Harmer, B. Yap, J. Wadsley, S. Clarke, L. Moss, A. Nicol et al., Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674-1685 (2012)
29. C. Schvartz, F. Bonnetain, S. Dabakuyo, M. Gauthier, A. Cueff, S. Fieffe et al., Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J. Clin. Endocrinol. Metab. 97, 1526-1535 (2012)
30. R.K. Alexander, P.R. Larsen, Radioiodine for thyroid cancer - is less more? New Engl. J. Med. 366, 1732-1733 (2012)
31. L. Wartofsky, Management of papillary microcarcinoma: primum non nocere. J. Clin. Endocrinol. Metab. 97, 1169-1172 (2012)
32. EANM, EANM procedure guidelines for therapy with iodine-131. Eur. J. Nucl. Med. 30, BP27-BP31 (2003)
33. J.C. Reynolds, in Comparison of I-131Absorbed Radiation Doses in Children and Adults; A Tool for Estimating Therapeutic I-131 Doses in Children. ed. by J. Robbins. Treatment of Thyroid Cancer in Children, (DOE/EH-0406, US Department of Commerce Technology Administration, National Technical Information Service, Springfield, 1994), pp. 127-135
34. M.D. Ringel, S.J. Burgun, in Recombinant Human Thyrotropin. ed. by L Wartofsky, D. Van Nostrand. Thyroid Cancer: A Comprehensive Guide to Clinical Management (Humana Press, Totowa, 2006), pp. 103-116
35. P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri et al., Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. 337, 888-896 (1997)
36. R.J. Robbins, R.M. Tuttle, M. Sonenberg, A. Shaha, R. Sharaf, H. Robbins, M. Fleisher, S.M. Larson, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11(9), 865-869 (2001)
37. R. Elisei, M. Schlumberger, A. Driedger, C. Reiners, R.T. Kloos, S.I. Sherman et al., Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 294, 4171-4179 (2009)
38. P.W. Rosario, A.F.M. Filho, R.X. Lacerda, M.R. Calsolari, Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Thyroid 222, 332-333 (2012)
39. C. Durante, S. Filetti, Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography. J. Clin. Endocrinol. Metab. 96, 3059-3061 (2011)
40. R.J. Robbins, S.M. Larson, N. Sinha, A. Shaha, C. Divgi, K.S. Pentlow, R. Ghossein, R.M. Tuttle, A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J. Nucl. Med. 43(11), 1482-1488 (2002)
41. F. Pacini, E. Molinaro, M.G. Castagna, F. Lippi, C. Ceccarelli, L. Agate, R. Elisei, A. Pinchera, Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 87(9), 4063-4068 (2002)
42. D. Barbaro, G. Boni, G. Meucci, G. Simi, P. Lapi, P. Orsini, C. Pasquini, F. Piazza, M. Caciagli, G. Mariani, Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J. Clin. Endocrinol. Metab. 88(9), 4110-4115 (2003)
43. F. Pacini, P.W. Ladenson, M. Schlumberger et al., Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab. 91, 926-932 (2006)
44. D. Van Nostrand, G.R. Khorjekar, J. O'Neil, S. Moreau, F.B. Atkins, P. Kharazi et al., Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131-I planar whole-body imaging and 124-I PET. J. Nucl. Med. 53, 359-362 (2012)
45. J. Klubo-Gwiezdzinska, K.D. Burman, D. Van Nostrand, M. Mete, J. Jonklaas, L. Wartofsky, Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid 22, 310-317 (2012)
46. H. Tala, R. Robbins, J.A. Fagin, S.M. Larson, R.M. Tuttle, Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J. Clin. Endocrinol. Metab. 96, 2105-2111 (2011)
47. S.J. Bonnema, S. Fast, L. Hedgedusw, Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131-I therapy. Endocrine 40, 344-353 (2011)